Literature DB >> 52000

Quality and quantity of survival in acute myeloid leukaemia.

P S Burge, T A Prankerd, J D Richards, M Sare, D S Thompson, P Wright.   

Abstract

The quality of life in leukaemia is as important as its quantity. In fifty-one patients the quality and quantity of life were improved by less aggressive treatment than is usual. By not trying to induce complete remission at all costs, the mobidity and early mortality were reduced and at least an equivalence in survival was obtained.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 52000     DOI: 10.1016/s0140-6736(75)90111-7

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  13 in total

Review 1.  Chemoprophylaxis.

Authors:  L P Garrod
Journal:  Br Med J       Date:  1975-12-06

2.  Prolonged remission maintenance in acute myeloid leukaemia.

Authors:  A S Spiers; J M Goldman; D Catovsky; C Costello; D A Galton; C S Pitcher
Journal:  Br Med J       Date:  1977-08-27

3.  Razoxane in treatment of acute myeloid leukaemia.

Authors:  D Shaw; G R Tudhope
Journal:  Br Med J       Date:  1978-10-14

4.  [Acute leukemias in elderly patients (author's transl)].

Authors:  K Grünewald; K Abbrederis; P Mittermaier; H Huber
Journal:  Blut       Date:  1982-05

Review 5.  Acute myeloid leukaemia: optimising treatment in elderly patients.

Authors:  Graham H Jackson; Penelope R A Taylor
Journal:  Drugs Aging       Date:  2002       Impact factor: 3.923

6.  Disease and illness. Distinctions between professional and popular ideas of sickness.

Authors:  L Eisenberg
Journal:  Cult Med Psychiatry       Date:  1977-04

7.  Prednimustine and vincristine compared with cytosine arabinoside and thioguanine for treatment of elderly patients with acute nonlymphoblastic leukemia.

Authors:  B Lönnqvist; B Andersson; M Björkholm; L Engstedt; G Gahrton; R Hast; G Holm; A Killander; B Lantz; D Lockner; H Mellstedt; J Palmblad; C Paul; C Peterson; B Simonsson; A M Stalfelt; A M Udén; B Wadman; G Oberg
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

8.  Measuring symptoms as a critical component of drug development and evaluation in hematological diseases.

Authors:  Loretta A Williams; Emre Yucel; Jorge E Cortes; Charles S Cleeland
Journal:  Clin Investig (Lond)       Date:  2013-12-01

Review 9.  Co-trimoxazole (trimethoprim-sulfamethoxazole): an updated review of its antibacterial activity and clinical efficacy.

Authors:  G P Wormser; G T Keusch; R C Heel
Journal:  Drugs       Date:  1982-12       Impact factor: 9.546

10.  Remission maintenance therapy in acute myelogenous leukemia.

Authors:  S H Embury; L Elias; P H Heller; C E Hood; P L Greenberg; S L Schrier
Journal:  West J Med       Date:  1977-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.